➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Express Scripts
Merck
Dow
AstraZeneca

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Patent: 7,320,961

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,320,961
Title:Method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
Inventor(s): Kempf; Dale J. (Libertyville, IL), Bertz; Richard J. (Kenosha, WI), Waring; Jeffrey F. (Franklin, WI)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/802,829
Patent Claims:see list of patent claims

Details for Patent 7,320,961

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Clinigen, Inc. PROLEUKIN aldesleukin For Injection 103293 1992-05-05 ⤷  Try it Free 2023-03-24
Partner Therapeutics, Inc. LEUKINE sargramostim For Injection 103362 1991-03-05 ⤷  Try it Free 2023-03-24
Partner Therapeutics, Inc. LEUKINE sargramostim Injection 103362 1991-03-05 ⤷  Try it Free 2023-03-24
Bayer Healthcare Pharmaceuticals Inc. BETASERON interferon beta-1b For Injection 103471 1993-07-23 ⤷  Try it Free 2023-03-24
Merck Sharp & Dohme Corp. PEGINTRON peginterferon alfa-2b Injection 103949 2001-01-19 ⤷  Try it Free 2023-03-24
Merck Sharp & Dohme Corp. SYLATRON peginterferon alfa-2b For Injection 103949 2011-03-29 ⤷  Try it Free 2023-03-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.